Long - $$$, science, management

$ for sure, it would be better to be negotiating from a position of strength and no call on the IP

Science, as incredible as it is, it's both an asset and a liability in our case. The liability comes from the potential erosion of sales from existing products of other drugs for potential buyers. If ABP has benefit for cardio, diabetes, kidney, liver, brain and lung(from the Uni of Nebraska study) then the potential damage to existing sales may outweigh the potential benefit ABP could give a potential bidder. Seeking a partner or outright buyer with zero or almost zero sales in those areas should be a focus. Having the potential of emergency use for COVID is a giant plus as potential near term revenue is a huge factor. The safety profile from BoM could be what ends up tipping the scales.

management - enough said

tada